Kalaris appoints Liisa Bayko as CFO; CAO Brett Hagen resigns

Kalaris Therapeutics, Inc.

Liisa Bayko appointed CFO and Treasurer effective July 20, 2026; base salary $475,000, target bonus 40%, option for 220,000 shares.
Brett Hagen resigns as SVP Finance and Chief Accounting Officer effective July 27, 2026.
Amy Vandekop, Corporate Controller, designated interim principal accounting officer effective July 27, 2026.
Bayko's option vests 25% on first anniversary, then monthly over 3 years; severance includes 9-12 months salary depending on change in control.
Bayko previously Managing Director at Evercore ISI and JMP Securities.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Liisa Bayko

Chief Financial Officer and Treasurer

KLRS · Kalaris Therapeutics, Inc.

Effective: 2026-07-20
Filed: July 20, 2026, 8:07 AM ET

On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Liisa Bayko was appointed as Chief Financial Officer and Treasurer at Kalaris Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the “Effective Date”).

View on SEC.gov

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-308382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.